SBIR/STTR Research Award

Enabling Toxoplasma gondii Kinome Directed Drug Discovery

Award identifier 3ed6d5e7182dfb7e10fac536dd6ccbcfc2475772bc587c0ec5f0c89b663c72a2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$225,000

Program and phase

SBIR · Phase I

Award year

2019

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LUCEOME BIOTECHNOLOGIES, L.L.C.
Proposal award date
2019-03-11
Contract end date
2021-03-10
UEI
PTPNMPNRP5R1
Solicitation number
PA18-574
Topic code
NIAID

Research abstract

Project Summary Toxoplasmosis is caused by a single celled apicomplexanToxoplasma gondiiT gondiiwhich invades host cells through ingestion of uncooked infected meat or contaminated waterT gondii infectsof the world s population and the current cost of the disease in US itself is estimated to be $ B and risingCurrent treatment regimen is effective only against acute infection and has severe side effectsHence there is an urgent need for new drugs and drug targetsThe genome of T gondiiis predicted to encodeactive kinasesKinases have been shown to be involved in every aspect of the life cycle of T gondiifrom invasion of host cells to virulenceHoweverthe lack of commercially available robust kinase assays has hindered T gondii kinome directed drug discoveryIn this applicationwe aim to develop and validate assays targeted against the kinases essential to the T gondii parasite s life cyclewhich is responsible for transmission and disease pathologyThese T gondii kinase specific assaysbased on our three hybrid split luciferase systemwill be further used for high throughput screening of a kinase targeted inhibitor libraryThese efforts are both significant and innovative as the identification of target specific inhibitors will not only provide pharmacophores for further drug development but also identify chemical probes for studying kinase biology and signaling pathways to provide new interventions Project Narrative Toxoplasma gondii is the causative agent of toxoplasmosisa debilitating disease in immunocompromised individualsand current treatments have been shown to have severe side effectsDevelopment of assays against new targets will help advance the discovery of new and effective therapies for this deadly diseaseThe purpose of our application is to develop low cost assays for the Toxoplasma gondii kinome

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

12 SBIR/STTR records share this UEI (2009–2023). Reported award amounts total $9,994,171. Reported amounts are not federal obligations.

Phases: Phase I, Phase II, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.